Alzheimer's Disease: Therapeutic Potential of Estrogen

This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease...

Date First Received: August 4, 2003

Last Updated: July 29, 2008

Verified by: National Institute on Aging (NIA), July 2008

Clinical Trial Phase: Phase 2/Phase 3 | Start Date: September 2001

Overall Status: Completed

Estimated Enrollment: 42

Brief Summary

Official Title: “Alzheimer's Disease: Therapeutic Potential of Estrogen”

Condition Keyword(s):

This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: January 2008

Detailed Clinical Trial Description

Estrogen is a naturally occurring hormone produced in a woman's body. The purpose of this 15-month study is to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease and without other dementias.

Patients who volunteer for this study will either receive a patch containing 17-ß-estradiol or will receive an inactive placebo patch. In addition, patients will be given either medroxyprogesterone or an inactive placebo pill. Neither the volunteers nor the study staff will know which type of patch or pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study medications on schedule. Patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 160 participants are being recruited.

Intervention(s) in this Clinical Trial

  • Drug: Transdermal estradiol
    • 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
  • Drug: Medroxyprogesterone
    • 2.5mg tablet daily for 12 months
  • Drug: Placebo Patch
    • Transdermal placebo patch, changed every 3 days, for 12 months
  • Drug: Placebo
    • Placebo tablet daily for 12 months

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 1
    • estradiol patch and medroxyprogesterone
  • Active Comparator: 2
    • estradiol patch and placebo pill
  • Active Comparator: 3
    • placebo patch and medroxyprogesterone
  • Placebo Comparator: 4
    • placebo patch and placebo pill

Outcome Measures for this Clinical Trial

Primary Measures

  • Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change
    • Time Frame: Baseline and 1, 3, 6, 12, and 15 months
      Safety Issue?: No

Secondary Measures

  • Skills of Independent Living: Physical functioning Performance (PFP)
    • Time Frame: Baseline and 1, 3, 6, 12, and 15 months
      Safety Issue?: No
  • Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)
    • Time Frame: Baseline and 1, 3, 6, 12, and 15 months
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)
  • Mini Mental State Examination score greater than 15/30

Exclusion Criteria:

  • History of cancer of reproductive tissues
  • History of deep vein thrombosis or blot clots
  • Diabetes
  • Heart disease or stroke
  • Liver problems including hepatitis
  • Severe vision or hearing problems
  • Tobacco use
  • Lack of an adequate caregiver
  • inability to perform psychometric testing

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 55 Years

Maximum Age for this Clinical Trial: 90 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: National Institute on Aging (NIA)

Overall Clinical Trial Officials and Contacts

Sanjay Asthana, MD Principal Investigator University of Wisconsin - Madison, William S. Middleton VA Hospital  

Related Publications

References

Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging. 2002;19(6):405-27. Review.

Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001 Aug 28;57(4):605-12.

Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999 Aug;24(6):657-77.

Additional Information

Information obtained from ClinicalTrials.gov on September 05, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00066157

Study ID Number: IA0048

ClinicalTrials.gov Identifier: NCT00066157

Health Authority: United States: Federal Government

University of Wisconsin Memory Research Program

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.